Related Experiment Videos
Drug differences between ACE inhibitors in experimental settings and clinical practice
A A Voors1, J H Kingma, W H van Gilst
1Department of Clinical Pharmacology, University of Groningen, The Netherlands.
Journal of Cardiovascular Risk
|October 1, 1995
Summary
Angiotensin converting enzyme (ACE) inhibitors show benefits after myocardial infarction. This review details structural and pharmacokinetic differences among ACE inhibitors to explain varied patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Growing evidence supports the use of angiotensin converting enzyme (ACE) inhibitors following myocardial infarction.
- Significant structural and functional variations exist among different ACE inhibitors.
Purpose of the Study:
- To review the structural, pharmacodynamic, and pharmacokinetic differences between various ACE inhibitors.
- To correlate these differences with expected variations in outcomes after myocardial infarction.
Main Methods:
- Review of existing experimental and clinical data on ACE inhibitors.
- Comparative analysis of drug structures, effects, and patient outcomes.
Main Results:
- ACE inhibitors exhibit distinct structural, pharmacodynamic, and pharmacokinetic profiles.
- These variations can lead to differential therapeutic effects and patient outcomes.
Conclusions:
- Understanding the specific properties of each ACE inhibitor is crucial for optimizing post-myocardial infarction treatment.
- Tailoring ACE inhibitor selection based on individual patient factors and drug characteristics may improve therapeutic efficacy.